251 related articles for article (PubMed ID: 31578594)
1. HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma.
Qi Y; Deng G; Xu P; Zhang H; Yuan F; Geng R; Jiang H; Liu B; Chen Q
Oncol Rep; 2019 Dec; 42(6):2309-2322. PubMed ID: 31578594
[TBL] [Abstract][Full Text] [Related]
2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
3. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
4. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
5. CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high‑grade glioma.
Wang K; Huang R; Li G; Zeng F; Zhao Z; Liu Y; Hu H; Jiang T
Oncol Rep; 2018 Oct; 40(4):2036-2046. PubMed ID: 30066946
[TBL] [Abstract][Full Text] [Related]
6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
7. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
8. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
Wang B; Ran Z; Liu M; Ou Y
Front Immunol; 2019; 10():1573. PubMed ID: 31379814
[TBL] [Abstract][Full Text] [Related]
10. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer.
Kula A; Dawidowicz M; Mielcarska S; Kiczmer P; Skiba H; Krygier M; Chrabańska M; Piecuch J; Szrot M; Robotycka J; Ochman B; Strzałkowska B; Czuba Z; Świętochowska E; Waniczek D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982953
[TBL] [Abstract][Full Text] [Related]
12. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
13. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
14. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
15. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
16. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
Yang G; Tang S; Zhang J; Qin L
World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
[TBL] [Abstract][Full Text] [Related]
17. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
18. The Significance of the Redox Gene in the Prognosis and Therapeutic Response of Glioma.
Niu H; Cao H; Liu X; Chen Y; Cheng Z; Long J; Li F; Sun C; Zuo P
Am J Clin Oncol; 2024 Jun; 47(6):259-270. PubMed ID: 38318849
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Front Immunol; 2022; 13():831101. PubMed ID: 35371079
[TBL] [Abstract][Full Text] [Related]
20. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
Wei L; Tang L; Chang H; Huo S; Li Y
Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
